Intellia Therapeutics, Inc. (NTLA)

NASDAQ: NTLA · IEX Real-Time Price · USD
63.49
+0.17 (0.27%)
At close: Aug 8, 2022 4:00 PM
63.80
+0.31 (0.49%)
After-hours: Aug 8, 2022 6:21 PM EDT
0.27%
Market Cap 4.83B
Revenue (ttm) 45.34M
Net Income (ttm) -400.43M
Shares Out 76.01M
EPS (ttm) -5.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,118,715
Open 63.97
Previous Close 63.32
Day's Range 61.83 - 64.95
52-Week Range 37.08 - 180.59
Beta 2.00
Analysts Buy
Price Target 131.26 (+106.7%)
Earnings Date Aug 4, 2022

About NTLA

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on... [Read more...]

Industry Biotechnology
IPO Date May 6, 2016
CEO John Leonard
Employees 485
Stock Exchange NASDAQ
Ticker Symbol NTLA
Full Company Profile

Financial Performance

In 2021, NTLA's revenue was $33.05 million, a decrease of -43.01% compared to the previous year's $57.99 million. Losses were -$267.89 million, 99.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 30 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is 131.26, which is an increase of 106.74% from the latest price.

Price Target
$131.26
(106.74% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat

Intellia Therapeutics (NTLA) posts a wider-than-expected Q2 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned

A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple. The post Intellia Gives Back Alnylam-Inspired Gains As Gene-Editin...

Other symbols: ALNY

Why Intellia Therapeutics Stock Is Sinking Today

Investors are reacting negatively to the company's Q2 update.

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -1.53% and 21.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies levera...

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?

Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted the...

Other symbols: ALNYBEAMCRSP

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates

CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics lev...

7 Cathie Wood Stocks Trading at a Discount Right Now

Cathie Wood stocks trading at a discount is our topic for today. The prominent fund manager and her team focus on disruptive innovation, considered by many to be a new paradigm in investing.

Other symbols: COINFATEMELITDOCTSLAZM

2 Biotech Stocks You'll Regret Not Buying on the Dip

BioCryst Pharmaceuticals and Intellia Therapeutics could storm back in the second half of 2022.

Other symbols: BCRX

7 Moonshot Investments Upending a $10 Trillion Industry

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on I...

Up 1,000% in 5 Years? Here Are 3 Stocks That Can Run That High

Here's why our roundtable likes Intellia Therapeutics, Doximity, and TransMedics.

Other symbols: DOCSTMDX

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of...

Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simula...

Other symbols: REGN

BMO Initiates Coverage On This Gene Editing Spearhead

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ: NTLA) with a Market Perform rating and a $54 target price.  The analyst says Intellia's gene-editing platform could potentially deliv...

5 Health Care Stocks Cathie Wood Favors

Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.

Other symbols: BEAMCRSPEXASTDOC

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatm...

CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-bas...

Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat

Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -76.58% and 8.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-base...

Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More

Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.

Other symbols: ENDPVIRVRTXZTS

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-b...

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platfo...

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapies leveraging CRISPR-base...

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics le...

3 Top Biotech Stocks Ready for a Bull Run

The hype has died down. Now it's time for science to take over.

Other symbols: BNTXREGN

3 Ominous Reasons to Avoid This Biotech Pioneer

They point to trouble for investors counting on a rebound.

Other symbols: CRSPEDIT

Thanks To These CRISPR Stocks, The Path To Rewriting Human DNA Is About To Get Pretty Fierce

Experts say CRISPR-based treatments could soon constitute a massive market — and the prospects are grabbing Big Pharma's attention. Investor's Business Daily has been helping people invest smarter resul...

Other symbols: EDIT